United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at Jefferies Healthcare Conference (Virtual) Transcript

Jun 01, 2021 / 07:30PM GMT
Release Date Price: €152
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Hi, everyone. This is Eun Yang, a biotech analyst at Jefferies. This is my pleasure to host a fireside chat with James Edgemond, Chief Financial Officer, United Therapeutics. As a reminder, if you -- James will be taking questions from the audience later. So feel free to type any questions you might have in the box on the (inaudible). So before we start Q&A, James, would you like to give us a short overview.

James C. Edgemond
United Therapeutics Corporation - CFO & Treasurer

I would, Eun. Thank you, and thank you for inviting Gil and I to this year's Jefferies Virtual Health Care Conference. We always appreciate the introduction. So thanks for having us. And what I would like to begin with a quick overview, 2021 has really already been an exciting year for UT. We've had 2 major product launches already and an NDA at the FDA. So it's only the beginning of June, but we've had launches with Remunity, which is our new subcutaneous pump, and we received approval for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot